TY - JOUR
T1 - Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation
T2 - How Not to Put the CART Before the Horse
AU - Kenderian, Saad S.
AU - Porter, David L.
AU - Gill, Saar
N1 - Funding Information:
Financial disclosure: This work was supported in part by grants from the University of Pennsylvania-Novartis Alliance (to S.G. and D.L.P.), an award from the National Cancer Institute (K12 CA090628, to S.S.K.), and a grant from the Predolin Foundation (to S.S.K.).
Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Hematopoietic cell transplantation (HCT) remains an important and potentially curative option for most hematologic malignancies. As a form of immunotherapy, allogeneic HCT (allo-HCT) offers the potential for durable remissions but is limited by transplantation- related morbidity and mortality owing to organ toxicity, infection, and graft-versus-host disease. The recent positive outcomes of chimeric antigen receptor T (CART) cell therapy in B cell malignancies may herald a paradigm shift in the management of these disorders and perhaps other hematologic malignancies as well. Clinical trials are now needed to address the relative roles of CART cells and HCT in the context of transplantation-eligible patients. In this review, we summarize the state of the art of the development of CART cell therapy for leukemia, lymphoma, and myeloma and discuss our perspective of how CART cell therapy can be applied in the context of HCT.
AB - Hematopoietic cell transplantation (HCT) remains an important and potentially curative option for most hematologic malignancies. As a form of immunotherapy, allogeneic HCT (allo-HCT) offers the potential for durable remissions but is limited by transplantation- related morbidity and mortality owing to organ toxicity, infection, and graft-versus-host disease. The recent positive outcomes of chimeric antigen receptor T (CART) cell therapy in B cell malignancies may herald a paradigm shift in the management of these disorders and perhaps other hematologic malignancies as well. Clinical trials are now needed to address the relative roles of CART cells and HCT in the context of transplantation-eligible patients. In this review, we summarize the state of the art of the development of CART cell therapy for leukemia, lymphoma, and myeloma and discuss our perspective of how CART cell therapy can be applied in the context of HCT.
KW - Adoptive T cell therapy
KW - Adoptive immunotherapy
KW - Bone marrow transplantation
KW - CART19
KW - Chimeric antigen receptor T cells
KW - Hematopoietic stem cell transplantation
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85006014368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006014368&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2016.09.002
DO - 10.1016/j.bbmt.2016.09.002
M3 - Review article
C2 - 27638367
AN - SCOPUS:85006014368
SN - 1083-8791
VL - 23
SP - 235
EP - 246
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 2
ER -